Avenue Therapeutics, Inc. (ATXI)

Avenue Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	2.86	2.59	1.78	6.71	3.76
Cash & Short-Term Investments	2.86	2.59	1.78	6.71	3.76
Cash Growth	10.06%	45.48%	-73.42%	78.26%	20.15%
Other Receivables	-	-	-	-	0.09
Receivables	-	-	-	-	0.09
Prepaid Expenses	0.08	0.08	0.07	0.14	0.11
Total Current Assets	2.93	2.67	1.85	6.85	3.96
Total Assets	2.93	2.67	1.85	6.85	3.96
Accounts Payable	0.72	0.3	0.4	0.15	0.36
Accrued Expenses	0.37	0.5	0.21	0.82	0.15
Other Current Liabilities	0	0.02	0.59	2.61	-
Total Current Liabilities	1.1	0.82	1.2	3.58	0.51
Total Liabilities	1.1	0.82	1.2	3.58	0.51
Common Stock	-	-	0	-	-
Additional Paid-In Capital	107.32	105.38	92.51	84.46	80.45
Retained Earnings	-105.49	-102.58	-90.93	-80.55	-77
Total Common Equity	1.83	2.8	1.58	3.91	3.45
Minority Interest	-	-0.94	-0.93	-0.64	-
Shareholders' Equity	1.83	1.86	0.65	3.27	3.45
Total Liabilities & Equity	2.93	2.67	1.85	6.85	3.96
Net Cash (Debt)	2.86	2.59	1.78	6.71	3.76
Net Cash Growth	10.06%	45.48%	-73.42%	78.26%	20.15%
Net Cash Per Share	0.91	2.00	12.63	230.24	249.06
Filing Date Shares Outstanding	3.29	3.15	0.59	0.08	0.02
Total Common Shares Outstanding	3.18	2.11	0.34	0.06	0.02
Working Capital	1.83	1.86	0.65	3.27	3.45
Book Value Per Share	0.58	1.33	4.64	61.35	184.09
Tangible Book Value	1.83	2.8	1.58	3.91	3.45
Tangible Book Value Per Share	0.58	1.33	4.64	61.35	184.09

Source: S&P Global Market Intelligence. Standard template. Financial Sources.